MedTrace Logo

Felodipine Event Reduction Study

NCT01136863 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9800

Last updated 2010-06-25

No results posted yet for this study

Summary

FEVER is an investigator-designed, prospective, multicentre,double-bind, randomized, placebo-controlled,parallel-group trial. The primary objective is to compare the long-term effects on the incidence of fatal and non-fatal stroke (and secondarily of other cardiovascular events) of administering a small dose of the calcium antagonist felodipine (5 mg once a day) or of a placebo, in hypertensive patients whose blood pressure had preliminarily been reduced by administering a low-dose diuretic (hydrochlorothiazide,12.5 mg once a day) to be continued in association with felodipine or placebo, throughout the trial.

Conditions

Interventions

DRUG

Felodipine

DRUG

Placebo

Sponsors & Collaborators

  • Shanxi Kangbao Pharmaceutical company

    collaborator UNKNOWN

  • Beijing Hypertension League Insititute

    collaborator UNKNOWN

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Lisheng Liu, MD · Fu Wai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-04-30
Primary Completion
2004-06-30
Completion
2004-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01136863 on ClinicalTrials.gov